Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)
![]() |
Text
275091.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 1MB |
Abstract
Background: Biomarker-driven prognostic models incorporating NT-proBNP and hs-cTnT in HFpEF are lacking. Aims: To generate a biomarker-driven prognostic tool for patients with chronic HFpEF enrolled in EMPEROR-Preserved. Methods: Multivariable Cox regression models were created for (i) the primary composite outcome of HF hospitalization or cardiovascular death (ii) all-cause death (iii) cardiovascular death and (iv) HF hospitalization. PARAGON-HF was used as a validation cohort. Results: NT-proBNP and hs-cTnT were the dominant predictors of the primary outcome, and in addition, a shorter time since last hospitalization, NYHA class III or IV, history of COPD, insulin-treated diabetes, low hemoglobin, and a longer time since HF diagnosis were key predictors (8 variables, all P<0.001). The consequent primary outcome risk score discriminated well (c-statistic=0.75) with patients in the top 10th of risk having an event rate >22x higher than those in the bottom 10th. A model for HF hospitalization alone had even better discrimination (c=0.79). Empagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure in patients across all risk levels. NT-proBNP and hs-cTnT were also the dominant predictors of all-cause and cardiovascular mortality followed by history of COPD, low albumin, older age, LVEF ≥50%, NYHA class III or IV and insulin-treated diabetes (8 variables, all P<0.001). The mortality risk model had similar discrimination for all-cause and cardiovascular mortality (c-statistic=0.72 for both). External validation provided c-statistics of 0.71, 0.71, 0.72, and 0.72 for the primary outcome, HF hospitalization alone, all-cause death, and cardiovascular death, respectively. Conclusions: The combination of NT-proBNP and hs-cTnT along with a few readily available clinical variables provides effective risk discrimination both for morbidity and mortality in patients with HFpEF. A predictive toolkit facilitates the ready implementation of these risk models in routine clinical practice.
Item Type: | Articles |
---|---|
Additional Information: | The EMPEROR-Reduced trial was supported by Boehringer Ingelheim and Eli Lilly and Company. Dr. Januzzi is supported in part by the Hutter Family Professorship at Harvard Medical School. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Kondo, Dr Toru and Ferreira, Mr Joao Pedro and McMurray, Professor John |
Authors: | Pocock, S. J., Ferreira, J. P., Packer, M., Zannad, F., Filippatos, G., Kondo, T., McMurray, J. J.V., Solomon, S. D., Januzzi, J. L., Iwata, T., Salsali, A., Butler, J., and Anker, S. D. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | European Journal of Heart Failure |
Publisher: | Wiley |
ISSN: | 1388-9842 |
ISSN (Online): | 1879-0844 |
Published Online: | 07 July 2022 |
Copyright Holders: | Copyright © 2022 The Authors |
First Published: | First published in European Journal of Heart Failure 24(10): 1869-1878 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record